Thus, we hypothesized that treatment of CU06-1004 allows the trafficking of anti-PD-1 into tumor central region via normalized vessels which leads to the expansion of tumor infiltrated lymphocytes instead of increasing the ability of effective infiltration of immune cells. The gene discussed is PDCD1; the disease is neoplasm.